July 20, 2023 News by Marisa Wexler, MS Phase 1 trial of bryostatin-1 in MS expected by year’s end Synaptogenix is teaming up with Cleveland Clinic for a Phase 1 clinical trial involving people with multiple sclerosis (MS) that will test the company’s lead candidate, bryostatin-1 ā a therapy designed to prevent cognitive deficits in MS patients. āWe are moving forward with our clinical development plans for…
February 24, 2022 News by Marta Figueiredo, PhD Bryostatin-1, Molecule to Protect Synapses, May Move Into MS Trials SynaptogenixĀ announced plans to advance bryostatin-1, its lead candidate, into clinical trials forĀ multiple sclerosisĀ (MS), marking the third neurological disease the small molecule therapy is being developed to potentially treat. āMultiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical…
June 16, 2020 News by Mary Chapman $7.2M NIH Grant Supports Study of MS Diagnostic Biomarker The National Institutes of Health (NIH) awarded a $7.2 million grant to a team led byĀ Cleveland ClinicĀ researchers that will study whether a new biomarker might more accurately diagnoseĀ multiple sclerosis (MS). Grant money will support a study in 400 adults suspected of having MS to determine if the…
April 28, 2020 News by Grace Frank Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
January 29, 2020 News by Marta Figueiredo, PhD New Imaging Agent of Myelin for Earlier MS Diagnosis, Myeliviz, Entering Clinical Testing TheĀ U.S. Food and Drug AdministrationĀ (FDA)Ā has agreed to allow Myeliviz, an imaging agent of myelin ā the protective layer that covers nerve fibers and isĀ damaged inĀ multiple sclerosisĀ (MS) ā to be evaluated in a clinical trial with healthy volunteers. Myeliviz, created byĀ Case Western Reserve UniversityĀ researchers, has the potential…
January 22, 2020 News by Mary Chapman Pilot Study Participant Helping Test Exoskeleton Device for MS Therapy Encouraged by Results Since being diagnosed with multiple sclerosis (MS) 20 years ago, Kathy Miskaās ability to walk has steadily worsened, especially in recent years. As a participant of a pilot study at the Cleveland Clinic Mellen Center for Multiple Sclerosis, however, she is cheered by the effect of…
January 20, 2020 News by Iqra Mumal, MSc Clinical Trial of Rhythmic Sound in Walking Rehab for MS Planned, MedRhythms Says MedRhythmsĀ is planning to soon open a pilot clinical trial to assess the safety and efficacy of its MR-004, its investigational product that uses rhythmic sounds to improve walking abilities in people withĀ multiple sclerosis (MS), the company announced. The randomized and controlled trial, fully support by a grant…
August 20, 2019 News by Ana Pena PhD Exploring Early Treatment Strategies for RRMS: An Interview with Neurologist Daniel Ontaneda When it comes to initial treatment selection for relapsing-remitting multiple sclerosis (RRMS), there is one question that has yet to be answered: Is it better to start with potentially safer moderately effective disease-modifying treatments (DMTs) or to hit the disease immediately with a high-efficacy DMT that may be…
May 15, 2019 News by Jose Marques Lopes, PhD #AANAM – 2 Trials Aim to Decide Best Early Way of Treating RRMS, Cleveland Clinic Doctor Says Two ongoing clinical trials may help doctors better understand which type of disease-modifying therapy ā those considered highly effective or those with low-to-moderate efficacy used in an escalating treatment approach ā would be best for people in the early stages of Ā relapsing-remitting multiple sclerosis (RRMS), according to a Ā …
March 15, 2019 Columns by Ed Tobias Pediatric MS Can Be āDiagnostic Odyssey’ A post in one of the MS social media groups I follow recently asked whether kids can have MS. The writer was worried about her 3-year-old. One commenter replied that her son was diagnosed when he was 9. But, she wrote, his symptoms actually began to appear when he…
March 1, 2019 News by Jonathan Grinstein #ACTRIMS2019 ā Use of Ocrevus at Cleveland Clinic Backs Phase 3 Trial Data Ocrevus (ocrelizumab) was shown to be aĀ highly effective therapy for people with multiple sclerosis (MS) in real-world clinical practice, according to Brandon Moss, MD, from theĀ Cleveland Clinic. The data was presented in a poster session Feb. 28, atĀ the Americas Committee…
February 26, 2019 News by Santiago Gisler Cleveland Clinic Chosen for Phase 2 Trial Testing NurOwn Stem Cell Therapy in Progressive MS Patients BrainStorm Cell Therapeutics announced theĀ Cleveland ClinicĀ is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the companyās NurOwn mesenchymal stem cell (MSC) therapy in individuals with progressive multiple sclerosis (MS). āWe are very excited to announce The Mellen Center for…
October 22, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Finding Best Treatment for ‘Right Patient’ and Progressive MS Among Work of Interest, Cleveland Clinic Doctors Say Tailored, highly effective therapies early in the disease’s course may be a way forward in multiple sclerosis (MS)Ā treatment, according to Cleveland Clinic neurologist Robert Bermel. Another neurologist with the Cleveland Clinic,Ā Robert Fox, talked about potential and upcoming progressive MS treatments.Ā In interviews with Multiple Sclerosis News…
September 18, 2018 News by Jose Marques Lopes, PhD Ibudilast Slows Brain Shrinkage 48% in Progressive MS Patients in Phase 2 Trial; Lead Researcher Says Finding is ‘Remarkable’ Progressive multiple sclerosis patients ā with primary or secondary progressive disease ā treated with high doses of oralĀ ibudilastĀ in a Phase 2 clinical trial showed a 48 percent slowing in the progression of brain atrophy, or shrinkage, relative to those given a placebo, study data show. What this…
August 22, 2018 News by Patricia Inacio, PhD Myelocortical MS, New Disease Subtype Marked by Nerve Cell But Not Myelin Loss, Identified in Study Researchers have identified a new subtype of multiple sclerosis (MS), one marked by nerve cell degeneration that occurs independently of immune system attacks against myelin, a process known as demyelination and considered a hallmark of MS. The new subtype ā called myelocortical MS ā is indistinguishable from others in the…
January 23, 2017 News by Patricia Silva, PhD MS Researcher at Cleveland Clinic Awarded $7M to Pursue Ways of Stopping Myelin Damage TwoĀ Cleveland Clinic researchers were awarded multi-year grants by the National Institutes of Health (NIH), underĀ itsĀ Outstanding Investigator Award,Ā to find new treatments for multiple sclerosis (MS) and other complex diseases. Bruce Trapp, PhD, an expert in myelin biology and MS, will receive about $7 million over eight years under the…
April 7, 2016 News by Patricia Silva, PhD MS Patients Asked to Take Part in Survey of Risk/Benefit Considerations in Choosing Treatments The National Multiple Sclerosis Society is funding a new survey to understand how people living with multiple sclerosis (MS) weigh risks against benefits when choosing MS therapies. The survey was developed by Dr. Robert Fox, a neurologist, working with colleagues at the Cleveland Clinic and the MS patient…
March 15, 2016 News by Margarida Azevedo, MSc New MS Survey Looks into Patients’ Appraisal of Risks, Benefits When Choosing Therapies A large-scale online survey, funded by the National Multiple Sclerosis Society Ā and developed by researchers,Ā is investigating how multiple sclerosis (MS) patients perceive and evaluate the risks and benefits of available therapies. InvestigatorsĀ encourage MS patients to participate in the survey, titled āMultiple Sclerosis Risk Tolerance,ā which can be…
September 4, 2014 News by Patricia Silva, PhD Walking Speed in MS Patients May Indicate Worsening of Disease A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as it is manifested in patients living with multiple sclerosis (MS), a neurodegenerative disease wherein the impulse-conducting myelin sheath is attacked by the body’s own…
May 7, 2014 News by Charles Moore Genzyme Enters Multi-Year MS Research Collaboration with Cleveland Clinic’s Academic Medical Center Cambridge, Massachusetts based biotech firm GenzymeĀ has formed a new research collaboration with Cleveland Clinic of Cleveland, Ohio with a focus on developing new therapeutic approaches to the treatment of Multiple Sclerosis (MS). More than 2.3 million people worldwide have been diagnosed with MS, including what is believed…